Free Trial

Alpha Cognition (NASDAQ:ACOG) Releases Earnings Results, Beats Estimates By $0.19 EPS

Alpha Cognition logo with Medical background

Key Points

  • Alpha Cognition (NASDAQ:ACOG) reported earnings of ($0.65) per share for the quarter, exceeding analyst estimates of ($0.84) by $0.19.
  • The company's stock price decreased by $1.99 during trading on Thursday, reaching $8.00, with a notable trading volume significantly above its average.
  • HC Wainwright has reiterated a "buy" rating on Alpha Cognition and set a target price of $20.00 for the shares.
  • Want stock alerts on Alpha Cognition? Get 5 Weeks of MarketBeat All Access for $5. Get My Stock Alerts.

Alpha Cognition (NASDAQ:ACOG - Get Free Report) released its earnings results on Thursday. The company reported ($0.65) earnings per share for the quarter, beating the consensus estimate of ($0.84) by $0.19, Zacks reports.

Alpha Cognition Stock Performance

Shares of Alpha Cognition stock traded down $1.99 during trading hours on Thursday, hitting $8.00. The company's stock had a trading volume of 233,385 shares, compared to its average volume of 89,692. The business has a 50 day moving average price of $9.70 and a two-hundred day moving average price of $7.38. Alpha Cognition has a 12-month low of $3.75 and a 12-month high of $11.54. The company has a market cap of $128.16 million, a PE ratio of -6.67 and a beta of 2.72.

Institutional Investors Weigh In On Alpha Cognition

A hedge fund recently bought a new stake in Alpha Cognition stock. Geode Capital Management LLC acquired a new position in shares of Alpha Cognition Inc. (NASDAQ:ACOG - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 11,992 shares of the company's stock, valued at approximately $112,000. Geode Capital Management LLC owned about 0.07% of Alpha Cognition at the end of the most recent reporting period.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a "buy" rating and set a $20.00 target price on shares of Alpha Cognition in a research report on Friday, May 16th.

Check Out Our Latest Analysis on ACOG

Alpha Cognition Company Profile

(Get Free Report)

Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.

Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Alpha Cognition Right Now?

Before you consider Alpha Cognition, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alpha Cognition wasn't on the list.

While Alpha Cognition currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Stocks With Explosive Upside
September Slowdown: 3 Stocks to Buy When the Pullback Comes
3 Overlooked Stocks Riding the AI Data Center Boom

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines